DRUG
Bright Minds Biosciences Inc.
NasdaqCMUSDEQUITY
Healthcare
DELAYED
Last price
77.42
▼ 1.14 (1.45%)
MARKET · —
Price
Chart style
Interval
Intraday intervals only cover recent history. The site picks the finest interval the range allows.
Overlays
Session levels
Lower pane
Tool
Drag pan · Pinch zoom · Hold crosshair · pick a tool then drag to draw
Open
81.00
Prev close
78.56
Day high
79.56
Day low
77.24
Volume
165.85K
Market cap
$759.65M
P/E (TTM)
—
52W range
38.00 – 123.75
Day trading desk
Gap from prior close
+3.11%
Prior close 78.56
VWAP
78.35
-1.19% from price
Relative volume
0.53×
Quiet session
Session range
4.87%
77.24 – 81.00
Position in range
5%
Near session low
ATR (14D)
3.90
5.03% of price
Prior day high
85.00
PDH
Prior day low
78.37
PDL
Bid / ask spread
—
Quote not published
Session volume
158.13K
Avg 300.42K
VWAP and the session figures are computed from the delayed intraday series on this page, so they lag the live tape and will not match a broker's real-time VWAP exactly. Turn on Prior day H/L/C, Opening range and Volume profile in the chart's Studies menu to see these levels drawn on price.
Trailing performance
Returnvs SPY
1W
+1.28%
+2.7%
1M
+8.60%
+4.9%
3M
-6.99%
-10.1%
6M
-9.43%
-20.5%
YTD
-0.79%
-13.1%
1Y
+79.96%
+60.0%
3Y
+2,900.78%
+2,826.6%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Free account
5 more panels on DRUG open with an account.
Options chains and analytics, valuation ratios, insider filings, analyst targets and ownership. No card, no trial, nothing to cancel.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
1.18M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Jun 12, 26 | McDonald (Ian) Director of Issuer |
BUY | 1.63K | $99.26K | Direct |
| Jun 3, 26 | Bottler (Nils Christian) Director of Issuer |
EXERCISE | 5.00K | $6.62K | Direct |
| Jun 3, 26 | Bottler (Nils Christian) Director of Issuer |
EXERCISE | 2.50K | $2.97K | Direct |
| Jun 1, 26 | Bottler (Nils Christian) Director of Issuer |
SELL | 5.00K | $425.85K | Direct |
| May 28, 26 | Vasilkevich (Alex) Senior Officer of Issuer |
EXERCISE | 4.50K | $17.11K | Direct |
| May 28, 26 | Vasilkevich (Alex) Senior Officer of Issuer |
EXERCISE | 5.00K | $5.99K | Direct |
| May 28, 26 | Vasilkevich (Alex) Senior Officer of Issuer |
EXERCISE | 35.00K | $47.01K | Direct |
| Apr 30, 26 | Vasilkevich (Alex) Senior Officer of Issuer |
SELL | 500 | $44.83K | Direct |
| Apr 30, 26 | Vasilkevich (Alex) Senior Officer of Issuer |
SELL | 2.00K | $178.23K | Direct |
| Apr 28, 26 | Cormorant Asset Management ,L.P 10% Security Holder of Issuer |
SELL | 109.33K | $9.79M | Direct |
| Feb 24, 26 | Fryzuk (Jeremy) Director of Issuer |
EXERCISE | 10.00K | $13.43K | Direct |
| Feb 24, 26 | Fryzuk (Jeremy) Director of Issuer |
EXERCISE | 7.50K | $9.03K | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
Bottler (Nils Christian) |
Director of Issuer | 5.00K | Exercise of options |
Cormorant Asset Management ,L.P |
10% Security Holder of Issuer | 950.00K | Acquisition or disposition in the public market |
Fryzuk (Jeremy) |
Director of Issuer | 30.61K | Exercise of options |
McDonald (Ian) |
Director of Issuer | 1.01M | Acquisition or disposition in the public market |
Vasilkevich (Alex) |
Senior Officer of Issuer | 21.75K | Exercise of options |
Fundamentals
Market cap$759.65M
Enterprise value$455.91M
Revenue (TTM)—
Gross profit—
EBITDA—
Net income$-24.51M
EPS (TTM)$-2.06
Free cash flow$-18.77M
Total cash$307.83M
Total debt$65.59K
Book value / share$22.59
Shares outstanding9.81M
Float6.21M
Short % of float11.78%
Dividend yield—
Beta (5Y)0.09
Valuation & profitability ratios
Trailing P/E—
Forward P/E-13.06
PEG ratio—
Price / sales—
Price / book3.43
EV / revenue—
EV / EBITDA—
Gross margin0.00%
Operating margin0.00%
Profit margin0.00%
Return on equity-13.63%
Return on assets-13.50%
Debt / equity0.02
Current ratio121.97
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | — |
| Operating revenue | $0 | $0 | $0 | $0 | — |
| Research & development | $11.08M | $1.18M | $5.00M | $12.18M | +839.4% |
| Selling, general & admin | $2.57M | $1.45M | $2.20M | $2.55M | +77.5% |
| Total operating expense | $13.94M | $2.82M | $7.39M | $14.98M | +393.8% |
| Operating income | -$13.94M | -$2.82M | -$7.39M | -$14.98M | -393.8% |
| Net interest income | $1.52M | $30.13K | $0 | $0 | +4,942.5% |
| Pre-tax income | -$12.23M | -$2.80M | -$7.37M | -$14.96M | -336.5% |
| Net income | -$12.23M | -$2.80M | -$7.37M | -$14.96M | -336.5% |
| Net income to common | -$12.23M | -$2.80M | -$7.37M | -$14.96M | -336.5% |
| Basic EPS | -1.78 | -0.65 | -1.98 | -6.06 | -173.8% |
| Diluted EPS | -1.78 | -0.65 | -1.98 | -6.06 | -173.8% |
| EBIT | -$13.94M | -$2.82M | -$7.39M | -$14.98M | -393.8% |
| EBITDA | -$13.86M | -$2.75M | -$7.31M | -$14.97M | -404.1% |
| Basic shares | 6.88M | 4.31M | 3.72M | 2.47M | +59.6% |
| Diluted shares | 6.88M | 4.31M | 3.72M | 2.47M | +59.6% |
| Line item | 2025 | 2024 | 2023 | 2022 | 2021 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $82.91M | $5.72M | $6.75M | $11.63M | — | +1,349.4% |
| Cash & short-term investments | $82.91M | $5.72M | $6.75M | $11.63M | — | +1,349.4% |
| Total current assets | $84.31M | $5.99M | $6.81M | $11.95M | — | +1,308.2% |
| Property, plant & equipment | $111.97K | $117.66K | $66.41K | $138.86K | — | -4.8% |
| Goodwill & intangibles | — | — | — | $0 | $2.00K | — |
| Total assets | $84.42M | $6.10M | $6.88M | $12.09M | — | +1,282.9% |
| Total current liabilities | $2.34M | $528.68K | $280.86K | $1.47M | — | +341.7% |
| Total debt | $125.78K | $118.96K | $73.55K | $139.91K | — | +5.7% |
| Total liabilities | $2.38M | $568.26K | $280.86K | $1.54M | — | +318.2% |
| Retained earnings | -$46.58M | -$34.35M | -$31.55M | -$24.17M | — | -35.6% |
| Shareholder equity | $82.04M | $5.54M | $6.60M | $10.54M | — | +1,381.9% |
| Working capital | $81.97M | $5.46M | $6.53M | $10.48M | — | +1,401.8% |
| Net tangible assets | $82.04M | $5.54M | $6.60M | $10.54M | — | +1,381.9% |
| Shares issued | 7.64M | 4.52M | 3.77M | 3.52M | — | +68.8% |
| Line item | 2025 | 2024 | 2023 | 2022 | YoY |
|---|---|---|---|---|---|
| Net income | -$12.23M | -$2.80M | -$7.37M | -$14.96M | -336.5% |
| Depreciation & amortisation | $76.87K | $73.36K | $72.45K | $6.04K | +4.8% |
| Stock-based compensation | $3.18M | $839.77K | $1.15M | $875.06K | +279.0% |
| Change in working capital | $554.99K | $39.81K | -$941.72K | $724.13K | +1,294.0% |
| Operating cash flow | -$8.69M | -$1.85M | -$7.02M | -$13.59M | -369.8% |
| Financing cash flow | $85.57M | $810.57K | $2.19M | $5.20M | +10,456.4% |
| Free cash flow | -$8.69M | -$1.85M | -$7.02M | -$13.59M | -369.8% |
| End cash position | $82.91M | $5.72M | $6.75M | $11.63M | +1,349.4% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | YoY |
|---|---|---|---|---|---|---|---|
| Total revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Operating revenue | $0 | $0 | $0 | $0 | $0 | — | — |
| Research & development | $13.05M | $5.66M | $4.78M | $2.69M | $2.56M | — | +130.5% |
| Selling, general & admin | $2.23M | $1.09M | $756.40K | $591.94K | $676.16K | — | +104.7% |
| Total operating expense | $15.32M | $6.90M | $5.66M | $3.30M | $3.35M | — | +121.9% |
| Operating income | -$15.32M | -$6.90M | -$5.66M | -$3.30M | -$3.35M | — | -121.9% |
| Net interest income | $2.69M | $818.26K | $529.54K | $476.23K | $509.38K | — | +228.7% |
| Pre-tax income | -$10.46M | -$7.57M | -$4.09M | -$5.24M | -$2.95M | — | -38.3% |
| Net income | -$10.46M | -$7.57M | -$4.09M | -$5.24M | -$2.95M | — | -38.3% |
| Net income to common | -$10.46M | -$7.57M | -$4.09M | -$5.24M | -$2.95M | — | -38.3% |
| Basic EPS | -1.09 | -0.97 | — | -0.74 | -0.42 | 0.01 | -12.4% |
| Diluted EPS | -1.09 | -0.97 | — | -0.74 | -0.42 | 0.01 | -12.4% |
| EBIT | -$15.32M | -$6.90M | -$5.66M | -$3.30M | -$3.35M | — | -121.9% |
| EBITDA | -$15.30M | -$6.88M | -$5.65M | -$3.28M | -$3.33M | — | -122.2% |
| Basic shares | 9.59M | 7.76M | — | 7.08M | 7.04M | 6.17M | +23.6% |
| Diluted shares | 9.59M | 7.76M | — | 7.08M | 7.04M | 6.64M | +23.6% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Cash & equivalents | $309.69M | $89.05M | $82.91M | $51.39M | $55.68M | +247.8% |
| Cash & short-term investments | $309.69M | $89.05M | $82.91M | $51.39M | $55.68M | +247.8% |
| Total current assets | $312.29M | $90.79M | $84.31M | $52.37M | $56.31M | +244.0% |
| Property, plant & equipment | $72.38K | $92.18K | $111.97K | $128.98K | $154.51K | -21.5% |
| Total assets | $312.37M | $90.88M | $84.42M | $52.50M | $56.47M | +243.7% |
| Total current liabilities | $3.83M | $1.58M | $2.34M | $604.99K | $637.97K | +142.2% |
| Total debt | $82.13K | $104.90K | $125.78K | $141.03K | $166.60K | -21.7% |
| Total liabilities | $3.83M | $1.60M | $2.38M | $667.83K | $726.81K | +139.6% |
| Retained earnings | -$64.60M | -$54.14M | -$46.58M | -$42.49M | -$37.25M | -19.3% |
| Shareholder equity | $308.53M | $89.28M | $82.04M | $51.83M | $55.74M | +245.6% |
| Working capital | $308.46M | $89.21M | $81.97M | $51.76M | $55.68M | +245.8% |
| Net tangible assets | $308.53M | $89.28M | $82.04M | $51.83M | $55.74M | +245.6% |
| Shares issued | 9.81M | 7.79M | 7.64M | 7.08M | 7.08M | +26.0% |
| Line item | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | YoY |
|---|---|---|---|---|---|---|
| Net income | -$10.46M | -$7.57M | -$4.09M | -$5.24M | -$2.95M | -38.3% |
| Depreciation & amortisation | $19.80K | $19.79K | $17.01K | $15.85K | $22.48K | +0.1% |
| Stock-based compensation | $1.20M | $1.29M | $1.07M | $1.32M | $615.91K | -6.2% |
| Change in working capital | $1.41M | -$996.37K | $1.19M | -$379.48K | -$138.63K | +241.4% |
| Operating cash flow | -$9.25M | -$5.82M | -$1.27M | -$3.50M | -$2.43M | -59.0% |
| Financing cash flow | $228.47M | $13.39M | $33.32M | -$16.87K | $225.38K | +1,606.1% |
| Free cash flow | -$9.25M | -$5.82M | -$1.27M | -$3.50M | -$2.43M | -59.0% |
| End cash position | $309.69M | $89.05M | $82.91M | $51.39M | $55.68M | +247.8% |
Options analytics
Put / call volume
—
—
Put / call open interest
—
Positioning, not flow
Max pain
75.00
-3.1% from spot
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
0
Contracts, this expiry
Put volume
2
Contracts, this expiry
Heaviest call OI
—
—
Heaviest put OI
75.00
1 contracts
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -1.64 | -0.24 | +85.3% |
| Mar 2026 | -1.26 | -1.09 | +13.5% |
| Dec 2025 | -1.19 | -0.97 | +18.1% |
| Sep 2025 | -1.00 | -0.58 | +41.8% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -1.33 | 6 | $0 | 0.0% |
| Next quarter | -1.84 | 4 | $0 | 0.0% |
| Current year | -3.65 | 6 | $0 | 0.0% |
| Next year | -8.17 | 6 | $30.25M | 0.0% |
Analyst targets & ownership
Mean target$171.19
High target$221.83
Low target$145.60
Implied upside121.11%
Analyst count3
ConsensusSTRONG BUY
Strong buy / Buy1 / 6
Hold0
Sell / Strong sell0 / 0
Held by insiders11.94%
Held by institutions94.85%
Institutions holding140
Price targets, consensus spread, insider and institutional ownership.
Moving averages & technicals
SMA 10
79.91
-3.11% from price
SMA 20
77.66
-0.31% from price
SMA 50
72.32
+7.05% from price
SMA 100
77.32
+0.13% from price
SMA 200
77.08
+0.45% from price
EMA 12
79.22
-2.27% from price
EMA 26
77.35
+0.09% from price
EMA 50
76.02
+1.84% from price
RSI (14)
50.3
Neutral
MACD (12,26,9)
1.87
Hist -0.12
ATR (14)
3.90
5.03% of price
Realised vol 30D
47.8%
Annualised
Bollinger upper
85.23
20, 2σ
Bollinger lower
70.08
20, 2σ
50 / 200 cross
Death
72.32 vs 77.08
Trend bias
Above 200
+0.45%
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Risk profile
Beta vs SPY
1.71
More volatile than market
Correlation to SPY
0.32
Loosely linked
Realised vol 30D
47.8%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-38.4%
Peak to trough
Max drawdown 5Y
-97.7%
Peak to trough
ATR 14
3.90
5.03% of price
Beta (reported)
0.09
5Y monthly, from filing
Short interest
Shares short
890.85K
Prior 952.51K
Change vs prior
-6.5%
Shorts covering
% of float
11.78%
Elevated
% of shares out
9.08%
Against total outstanding
Days to cover
3.4
Liquid
Float
6.21M
Freely tradeable shares
Exchanges publish short interest twice a month with a settlement lag, so this is roughly two weeks behind. Days to cover divides shares short by average daily volume — it estimates how long covering would take, not whether it will happen.
Rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 19, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Aug 17, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jun 1, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| May 20, 26 | Piper Sandler | MAINTAINED | Overweight | Overweight |
| Apr 13, 26 | Jefferies | INITIATED | — | Buy |
| Mar 30, 26 | BTIG | MAINTAINED | Buy | Buy |
| Mar 4, 26 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
| Feb 17, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jan 7, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jan 6, 26 | BTIG | MAINTAINED | Buy | Buy |
| Jan 2, 26 | Chardan Capital | MAINTAINED | Buy | Buy |
| Dec 30, 25 | HC Wainwright & Co. | MAINTAINED | Buy | Buy |
Dividends & splits
Forward rate—
Forward yield—
5-year avg yield—
Payout ratio0.00%
Ex-dividend date—
Next pay date—
Last split1:5
Split dateJul 14, 2023
SEC filings
Corporate Changes & Voting Matters
6-K · 2026-08-17
Offering Registrations
S-8 · 2026-08-13
Corporate Changes & Voting Matters
6-K · 2026-06-03
Corporate Changes & Voting Matters
6-K · 2026-06-02
Corporate Changes & Voting Matters
6-K · 2026-05-28
Corporate Changes & Voting Matters
6-K · 2026-05-20
Corporate Changes & Voting Matters
6-K · 2026-02-13
Corporate Changes & Voting Matters
6-K · 2026-01-09
Headlines
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 97.4%: Read This Before Placing a Bet
Zacks · 13d ago
Wall Street Analysts See a 107.53% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?
Zacks · 31d ago
All You Need to Know About Bright Minds Biosciences Inc. (DRUG) Rating Upgrade to Strong Buy
Zacks · 32d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.